Humira®/Biosimilars Forecast for 2023 and Beyond
The biosimilars for the blockbuster drug Humira® will hit the market in 2023.
Join our team as we discuss the complexities surrounding biosimilars, how they may influence the pharmacy landscape and the important considerations employers should know. We look forward to having you attend the event!
Andrea Grance, R.Ph.
Principal, Brown & Brown
Vice President, PillarRx (part of the Brown & Brown team)
Director of Learning & Development for Employee Benefits, Brown & Brown
Retail Vice President
DISCLAIMER: Brown & Brown, Inc. and all its affiliates, do not provide legal, regulatory or tax guidance, or advice. If legal advice counsel or representation is needed, the services of a legal professional should be sought. The information in this document is intended to provide a general overview of the topics and services contained herein. Brown & Brown, Inc. and all its affiliates, make no representation or warranty as to the accuracy or completeness of the document and undertakes no obligation to update or revise the document based upon new information or future changes.